Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | FPR2 | P25090 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.30 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2047677 | 0.81 | BRD4 (0.42) | FPR2LMNA | |
| SCHEMBL2047876 | 0.81 | BRD4 (0.42) | FPR2LMNA | |
| SCHEMBL2052237 | 0.81 | BRD4 (0.42) | FPR2LMNA | |
| SCHEMBL4167991 | 0.81 | BRD4 (0.42) | FPR2LMNA | |
| SCHEMBL2052239 | 0.81 | BRD4 (0.42) | FPR2LMNA | |
| SCHEMBL4162762 | 0.79 | MEN1 (0.43) | TDP1LMNAALDH1A1 | |
| SCHEMBL4162770 | 0.79 | MEN1 (0.43) | TDP1LMNAALDH1A1 | |
| SCHEMBL14140427 | 0.79 | CYP19A1 (0.40) | ALDH1A1 | |
| SCHEMBL14144956 | 0.79 | SIGMAR1 (0.31) | FPR2LMNA | |
| SCHEMBL14140687 | 0.79 | SIGMAR1 (0.31) | FPR2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8217027-B2 | Sphingosine-1-phosphate receptor agonist and antagonist compounds | ABBOTT LABORATORIES (US) | 2012-07-10 | — | — | US | disclosed |
| EP-2120575-A1 | SPHINGOSINE-1 -PHOSPHATE RECEPTOR AGONIST AND ANTAGONIST COMPOUNDS | Abbott Laboratories (US) | 2009-11-25 | — | — | EP | disclosed |
| US-20090029947-A1 | Sphingosine-1-phosphate receptor agonist and antagonist compounds | ABBVIE INC. | 2009-01-29 | — | — | US | disclosed |
| WO-2008079382-A1 | SPHINGOSINE-1 -PHOSPHATE RECEPTOR AGONIST AND ANTAGONIST COMPOUNDS | ABBOTT LABORATORIES (US) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029947-A1 | Sphingosine-1-phosphate receptor agonist and antagonist compounds | S1PR1, S1PR3, S1PR5 | TDP1 2767/4885HDAC8 2452/4885HDAC6 2343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.